Strategic Equity Capital plc · LSE:SEC
Strategic Equity Capital — Q3 2019 Earnings Presentation
37 slides from Strategic Equity Capital's earnings presentation, 2019
Slide 1: Strategic Equity Capital plc Q3 Update 2019
STRATEGIC EQUITY CAPITAL PLC Q3 Update 2019
Slide 2: Risk considerations
Risk considerations Risk Factors for Strategic Equity Capital plc (the Company”) – The general risk factors set out under the heading “D.1.Key Risks” of the Prospectus apply to the Company. In addition, potential investors should note the following factors: • There can be no guarantee that the inves
Slide 3: Notice to recipients
Notice to recipients This document is given to the recipient on condition that the recipient accepts that it is not a client of GVQ Investment Management Limited (“GVQIM”) and that hence, none of the client protections applicable to GVQIM’s clients are in fact in force or available, and GVQIM is not
Slide 4: Contents
Contents Q3 Update 2019 • Executive Summary 6 • Performance 7 • Detailed portfolio analysis 8 Outlook 13 Conclusion 22 Appendix 24 4
Slide 5: Q3 Update 2019
Q3 UPDATE 2019
Slide 6: Executive summary
Executive summary • SEC (the “Trust”) net assets per share decreased by 1.1%¹ over Q3. The FTSE Small Cap ex IT index (the “index”) decreased by 1.2%¹ • In 2019 YTD, the NAV per share has increased by 12.2%. This compares favourably with the FTSE Small Cap ex IT and FTSE AIM indices, which have incr
Slide 7: Fund performance
Fund performance Annualised 15 13.7 13.2 12.2 10.5 10 8.4 5.9 5.7 4.9 5 3.0 1.7 0.2 0 -1.1 -1.2 -5 -7.8 -10 3 months YTD 1 year 7 Feb 2017* 3 years 5 years 7 years SEC NAV Total Return FTSE Small Cap x IT Total Return Average 7.8% 8.0% 7.7% 8.3% 9.1% 9.4% 9.8% Net Cash Strong NAV return over the med
Slide 8: Q3 Attribution analysis
Q3 Attribution analysis Positive attribution bps GVQIM Comment Proactis 81 In-line full year results. In response to inbound interest, the company commences a Formal Sales Process Full year results, first under the new CEO with a return to organic growth. Shares remain very attractively Wilmington 7
Slide 9: Changes to top 10 holdings
Changes to top 10 holdings Top 10 Q2 2019 Top 10 Q3 2019 Company % of portfolio Company % of portfolio Equiniti Group 12.2 Equiniti Group 12.4 Tyman Group 6.6 Wilmington 7.8 Clinigen Group 6.5 Clinigen Group 7.3 Tribal Group 6.5 Tyman Group 6.7 Wilmington 6.4 Tribal Group 5.6 4imprint Group 6.3 Ergo
Slide 10: Top 10 holdings
Top 10 holdings1 GVQIM GVQIM Net debt/ Company Sector Funds % of CF yield2 Investment thesis EBITDA NTM3 company NTM3 High quality market leader in defensive and structurally growing market. Ability to grow Support through demonstrable cross-sell, penetrating the North American market and through se
Slide 11: Highly concentrated and unconstrained portfolio
Highly concentrated and unconstrained portfolio Sector exposure by value Value by market cap band 1 Healthcare 26.6% 12 1 <£50m 1.9% 8 9 7 7 2 Support services 18.4% 2 £50m - £100m 0.0% 1 3 6 3 Technology 15.8% 3 £100m - £200m 28.2% 4 Financials 11.1% 4 £200m - £300m 13.1% 6 5 5 Industrials 8.4% 5 £
Slide 12: Portfolio valuation
Portfolio valuation1 SEC SEC FTSE UK Small Cap ex weighted average median investment trusts Number of securities 21 21 154 Market cap (£m) 442 271 313 Consensus EV/EBITDA FY1 9.3x 9.5x 7.0x Consensus price earnings FY1 13.2x 13.2x 7.5x Consensus FY1 earnings growth 9.3% 10.0% 7.0% Consensus dividend
Slide 13: Outlook
OUTLOOK
Slide 14: Small companies are currently out of favour
Small Companies are currently out of favour… 400% Figure 1: 10 year cumulative performance by sector 300% • Small companies tend to outperform over the longer term (Figure 1) 200% 100% • This is a function of their greater ability to grow (from a smaller base) and being less well known and not as wi
Slide 15: Negative flows and poor liquidity
…coupled with negative flows and poor liquidity… IA UK Smaller Companies Funds cumulative net flows % of free float traded / month – FTSE Small Cap £0m 7% -£150m 6% -£300m 5% 4% -£450m 3% -£600m 2% -£750m 1% 0% -£900m 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 20
Slide 16: Valuation divergence has rarely been wider
Valuation divergence has rarely been wider FTSE Small Cap valuation discount to FTSE All Share (in P/E multiple terms) over time 1.0x 0.5x 0.0x -0.5x -1.0x -1.5x -2.0x -2.5x -3.0x 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 Small Cap discount t
Slide 17: Global private equity dry powder at record highs
Whilst global private equity dry powder levels are at record highs Private Equity Dry Powder by Fund Type, 2009 - YTD2019 Global public-to-private deal value $1,400bn $500 bn 200 $1,200bn $1,000bn $400 bn 150 Deal count Deal value $800bn $300 bn $600bn 100 $200 bn $400bn 50 $200bn $100 bn $0bn $0 bn
Slide 18: Global private equity financing is generationally low
Global private equity financing is generationally low Investor views on funds types presenting the best opportunities1 HY bond yields over time (Bloomberg global high yield bond index) 2 25% Buyout - Small to mid-market 54% Growth 29% 20% Secondaries 23% Buyout - Large to mega 18% 15% VC - Early sta
Slide 19: Multi-year bearishness around UK equities
Multi-year bearishness around UK equities Price and trailing DPS of UK MSCI index over time 240 200 160 120 80 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 Price Trailing DPS Highly negative view of UK equities reflected in >£12bn of net outflows from UK funds
Slide 20: Bear market checklist
Bear market checklist Start of Proper Bear Markets Mar-00 Oct-07 Now Global Equity Valuations Trailing PE 33 17 18 Fwd PE 24 14 15 DY 1.3 2.1 2.5 CAPE 48 30 24 Global Equity Risk Premium 1.0% 3.3% 5.2% US Yield Curve (10Y minus 2Y) -0.5 0.0 0.0 Sentiment Global Analyst Bullishness (std dev) 1.7 1.0
Slide 21: Earnings growth, cashflow and M&A to drive returns
Earnings growth, cashflow and M&A to drive returns SEC portfolio • Double digit aggregate earnings • Private Equity ‘dry powder’ at record growth for the portfolio levels. Any resolution to UK uncertainty could see acquirers • Portfolio growth exceeds the market, return despite portfolio’s much lowe
Slide 22: Conclusion
CONCLUSION
Slide 23: Conclusion
Conclusion • SEC’s net assets per share (“NAV”) decreased by 1.1%¹ over Q3, whilst the FTSE Small Cap ex IT index decreased by 1.2% • In 2019 YTD, the NAV per share has increased by 12.2%. This compares favourably with the FTSE Small Cap ex IT and FTSE AIM indices, which have increased by 4.9% and 2
Slide 24: Appendix
APPENDIX
Slide 25: Equiniti – a reminder of the thesis
Equiniti – a reminder of the thesis Equiniti – a market leading specialist technology and business process outsourcer • Customers include 70% of FTSE 100 • High value on the strength of cash flows companies and 70% of newly listed and structural growth drivers to both PE companies and trade: • Oppor
Slide 26: IFG Group – takeover case-study
IFG Group – takeover case-study 2.00 Company announces proposed sale of Saunderson • On 25 March 2019, a recommended cash offer was made by Epiris House and potential Elysian Fuels liability Funds at 193p, a 46% premium to the closing share price, a trailing 1.90 PE valuation of 21.4x. SEC owned 9.9
Slide 27: Medica Group – a recap of the company
Medica Group – a recap of the company 40% 25 6 35% 4 20 30% 2 Operating margin 25% 0 15 Sales £m £m 20% -2 15% 10 -4 10% -6 5 5% -8 0% 0 -10 H117 H217 H118 H218 H119 H117 H217 H118 H218 H119 Sales EBITDA margin Operating cash flow Net debt/cash No. of reporters 267 306 339 362 390 • Since listing, t
Slide 28: Medica Group – Investment Thesis
Medica Group – Investment Thesis Medica Group – the UK’s leading teleradiology provider • Average sales growth rate of c.17% • High growth, predictable revenue since IPO. All organic streams and low capital intensity are coveted by financial buyers • This growth is supported by multiple long term st
Slide 29: Portfolio investment themes
Portfolio investment themes DIVERSIFIED DIGITAL HEALTH REGULATION AND PENSIONS INFRASTRUCTURE PHARMA COMPLIANCE AND AND SAVINGS BUILDING Demographic and Digital maturity agenda; Increase in complexity US single family Increasing compliance population changes replacement of legacy and regulatory burd
Slide 30: How we identify value in potential investments
How we identify value in potential investments Main focus of most Main focus of most PUBLIC EQUITY INVESTORS PRIVATE EQUITY INVESTORS All investments undergo All investments are valued in-house, prospective using an in house cash-flow and historic leveraged buy-out model modelling Focus on recent re
Slide 31: Asset quality
There are strict criteria for inclusion in our funds Speculative Fair valued GARP1 Under valued Recovery Turnaround Distress growth A A Investment Asset quality Asset quality focus B Avoid Avoid B C Avoid C GVQIM’s research process aims to identify high quality coveted assets with attractive cash fl
Slide 32: How we identify coveted assets
How we identify coveted assets We look for characteristics which GVQIM believes potential acquirers value highly Qualitative Quantitative • Niche market leaders • High and/or improving ROCE • Orderly end markets, with some growth • Strong cash conversion • Sustainable business model/franchise/unique
Slide 33: Our Black List screens out companies with fundamental business risks
Our Black List screens out companies with fundamental business risks Operational • Excessive reliance on a single product, customer, supplier or distributor • The primary driver of profitability cannot be influenced by management (e.g. resources) • Inherently low margins • Structurally declining mar
Slide 34: Research Committee ensures consistency of approach
Research Committee ensures consistency of approach Preliminary Investment Final Investment Monitoring Idea generation Investment Memorandum Recommendation & review Recommendation Materials • Watch list • Company description • Company meeting • Counterparty analysis • Progress against • M&A transacti
Slide 35: Long term track record
Long term track record Cumulative rebased total returns1 300 CAGR¹ 280 SEC NAV 18.2% 260 240 220 200 180 160 FTSE Small Cap ex IT 11.8% 140 120 100 80 60 40 Jun 09 Jun 10 Jun 11 Jun 12 Jun 13 Jun 14 Jun 15 Jun 16 Jun 17 Jun 18 Jun 19 Strong cumulative performance since process improvements in June 2
Slide 36: Performance
Performance Calendar Year annual performance YTD 2019 2018 2017 2016 2015 2014 2013 2012 Share Price Total Return 12.0% -17.6% 20.2% -9.0% 14.2% 32.7% 61.5% 25.6% NAV Total Return 12.2% -14.1% 21.7% 6.3% 12.1% 18.1% 46.1% 21.3% FTSE Small Cap ex Investment Trusts Total Return 4.9% -13.8% 15.6% 12.5%
Slide 37: Contact details
Contact details For further information regarding the SEC please contact the GVQ Investment Management marketing team below, or visit the Company’s website: www.strategicequitycapital.com For general enquiries, please contact: GVQ Investment Management Limited 16 Berkeley Street, London, W1J 8DZ Tel
Strategic Equity Capital — Q3 2019 Earnings Presentation on 6ix